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Abstract
Background: Methicillin-resistant Staphylococcus aureus (MRSA) is an important nosocomial pathogen but little is
known about its circulation in hospitals in developing countries. We aimed to describe carriage of S.aureus amongst
inpatients in a mid-sized Kenyan government hospital.
Methods: We determined the frequency of S.aureus and MRSA carriage amongst inpatients in Thika Hospital, Kenya
by means of repeated cross-sectional ward surveys. For all S.aureus isolates, we performed antibiotic susceptibility
tests, genomic profiling using a DNA microarray and spa typing and MLST.
Results: In this typical mid-sized Kenyan Government hospital, we performed 950 screens for current carriage of S.
aureus amongst inpatients over a four month period. We detected S.aureus carriage (either MSSA or MRSA) in 8.9%
(85/950; 95%CI 7.1-10.8) of inpatient screens, but patients with multiple screens were more likely have detection of
carriage. MRSA carriage was rare amongst S.aureus strains carried by hospital inpatients – only 7.0% (6/86; 95%CI
1.5-12.5%) of all isolates were MRSA. Most MRSA (5/6) were obtained from burns patients with prolonged admissions,
who only represented a small proportion of the inpatient population. All MRSA strains were of the same clone
(MLST ST239; spa type t037) with concurrent resistance to multiple antibiotic classes. MSSA isolates were diverse and
rarely expressed antibiotic resistance except against benzyl-penicillin and co-trimoxazole.
Conclusions: Although carriage rates for S.aureus and the MRSA prevalence in this Kenyan hospital were both low,
burns patient were identified as a high risk group for carriage. The high frequency of genetically indistinguishable
isolates suggests that there was local transmission of both MRSA and MSSA.
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Background
Staphylococcus aureus is both a human commensal and
an important pathogen [1]. Methicillin-resistant S.aureus
(MRSA) is a common cause of healthcare-associated in-
fections in both developed and developing countries,
though limited information is available from the latter
[2]. In hospital wards in developing countries, the risk of
nosocomial transmission is likely to be high due to close
physical proximity of patients, inadequate staffing, unre-
liable water-supply for handwashing, lack of alcohol
hand-rub, isolation facilities or expertise for infection
control [3] - these could represent near-ideal conditions
for nosocomial circulation of drug-resistant bacteria. In
sub-Saharan Africa, screening for MRSA carriage during
hospital admission is rarely considered a healthcare pri-
ority and is infrequently performed, so patients carrying
MRSA in hospitals in this region are unlikely to be iden-
tified or isolated.
Carriage of S.aureus is most commonly detected in the
anterior nares (nostrils), though other sites on the body
are frequently colonised, most commonly the groin and
the axillae [1]. Isolates from the nares are normally in-
distinguishable by molecular typing from those found on
other body sites [4]. Most S.aureus infections originate
from self-carried strains, although disease only develops
in a small minority of carriers [4,5]. Cross-sectional
studies in adult populations have typically found nasal
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carriage rates of around 25%, although much of this
work has been conducted in high-income settings [1].
Carriage of S.aureus (either MRSA or methicillin-sensitive
S.aureus (MSSA)) often lasts from months to years, and
tends to be longer amongst individuals with chronic skin
disease [6].
MRSA expresses resistance to all β-lactam antibiotics
(penicillins, cephalosporins, carbapenems) by producing
a penicillin-binding protein (PBP2a) from the mecA gene
in the staphylococcal cassette chromosome (SCCmec).
MRSA was first described in 1961 in the UK, very soon
after the introduction of anti-staphylococcal penicillins
[7]. Some of the earliest reports of MRSA in sub-Saharan
African came from various Kenyan Hospitals (including
Thika Hospital) in the early 1990’s, where it was princi-
pally found amongst burns patients [8]. The prevalence
of MRSA is the percentage of a collection of S.aureus iso-
lates expressing resistance to methicillin – a marker for
the presence of mecA. This has been estimated in a small
number of studies in sub-Saharan Africa over the past
25 years, mostly based on clinical (disease-causing) iso-
lates obtained at university teaching hospitals in major
cities [9-12]. However, there are relatively few studies
examining the prevalence of S.aureus carriage and of
MRSA amongst these carriage isolates from patient pop-
ulations in sub-Saharan Africa [13-18] – see Table 1.
These studies show considerable variation in MRSA car-
riage prevalence amongst inpatient groups: from as high
as 21% amongst TB inpatients in Tulega Ferry, South
Africa to as low as 1.3% amongst a population compris-
ing paediatric and surgical inpatients in Accra, Ghana - it
is unclear what gives rise to this diversity.
Most MRSA strains in Africa appear to derive from
a small number of common ancestors: a recent study
examining 86 MRSA isolates from clinical isolates at
five hospitals in West Africa and Madagascar found
that 88% of these isolates were from one of three clonal
strains [12]. By contrast, there was wide diversity amongst
MSSA clones from the same institutions [11]. No simi-
lar studies have been reported from East Africa and
the types of MRSA circulating in East Africa are largely
unknown.
We aimed to describe the prevalence and diversity of
MSSA and MRSA carriage amongst inpatients in a typ-
ical mid-sized public-service hospital in Kenya.
Methods
Study setting and patient procedures
Thika Level 5 Hospital is a 300-bed Government Hospital
in the town of Thika, approximately 50 km north-east of
Nairobi, in Central Province, Kenya. It provides medical,
surgical, gynaecological, obstetric and paediatric services to
a mixed urban and rural population and has a total of
seven inpatient wards. Throughout this study there was no
full-time infection control nurse in Thika Hospital, though
a Hospital Infection Prevention and Control Committee
met monthly. Daily bed occupancy rates in adult wards in
2011 were typically between 120 and 140% and all patients
were nursed in communal bays.
Between the 11th July and 7th November 2011, each
week all current inpatients in two out of the five adult
inpatient wards (rotating between male and female med-
ical, male and female surgical and gynaecological) were
screened for carriage of S.aureus. Any patients who
stayed in the ward overnight prior to screening were eli-
gible for inclusion, provided that they (or a family member)
were able to give consent. The surgical wards included
some paediatric patients receiving treatment for surgical
conditions, who were also included in screening. Patients
who were MRSA-negative were repeatedly screened
throughout their entire period of hospitalisation, resulting
in some patients being screened multiple times. Initial re-
sults regarding MRSA carriage were relayed to patients
and clinicians as soon as these became available. Patients
found to have carriage of MRSA were subsequently treated
with vancomycin if an infection with S.aureus was sus-
pected. Patient data were collected from patient notes or
by direct interview during screening and single-entered
into a local database. Statistical analysis was carried out
using STATA v12.
Table 1 Estimates of carriage of S.aureus and MRSA in patient populations in sub-Saharan Africa
Study location Carriage isolates from Proportion with
S.aureus carriage
S.aureus
carriage rate
Proportion of
MRSA/S.aureus
MRSA Overall MRSA
carriage rate
Mogadishu, Somalia [13] Paediatric inpatients 21/46 46% 1/21 5% 2.2%
Tulega Ferry, South Africa [14] Inpatients with TB 13/52 25% 11/13 85% 21%
Lagos, Nigeria [15] HIV + patients (outpatients) 124/374 33% 20/124 16% 5.3%
Lambaréné, Gabon [16] Sickle-cell disease paediatric
outpatients
34/73 47% 1/34 2.9% 1.4%
Ife-Ife, Nigeria [17] Patients on admission to
surgical wards
61/192 32% 7/61 11% 3.6%
Accra, Ghana [18] Inpatients (Paediatric and
Surgical Departments)
63/452 14% 6/63 10% 1.3%
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Ethics statement
This study was approved by the Kenya Medical Research
Institute National Ethical Review Committee. All pa-
tients (or their relatives) gave written informed consent
to nasal and skin swab collection.
Swab processing
Paired nasal and axillary skin swabs were collected from
each patient and were immediately transferred to Man-
nitol Salt broth (HiMedia Laboratories, Mumbai, India)
for overnight selective enrichment. The following day,
aliquots were plated onto Blood Agar (BA) media. Single
colonies from plates which showed suspected S.aureus
colony growth, were further processed by Gram stain,
catalase and coagulase test, and checked for the ability
to hydrolyse DNA. Disc diffusion tests with cefoxitin
(10 μg) were used to identify suspected MRSA according
to British Society for Antimicrobial Chemotherapy guide-
lines. All media were locally prepared and batch controlled
using appropriate internal quality control strains (S.aureus
ATCC 25923, S.epidermidis ATCC 12228, E.coli ATCC
25922). These initial screening tests were performed in
Thika Hospital, Kenya. Isolates were initially kept at −20°C
and then transferred to −80°C for storage. Isolates were
later shipped to the University Medical Centre Groningen,
the Netherlands for further investigations.
Antimicrobial susceptibility testing
Susceptibility to a standard panel of antibiotics plus chlor-
amphenicol was performed using the automated Vitek 2
system (bioMerieux, Marcy l’Etoile, France). The results
were interpreted in accordance with the 2012 guidelines of
the Clinical and Laboratory Standards Institute. Isolates
positive for inducible clindamycin resistance were assumed
to be resistant to lincosamines and macrolides.
Extraction of genomic DNA
Total DNA was prepared from a loop of S.aureus cells
lifted from blood agar plates and transferred to 2-ml
tubes containing 500 μl of water and zirconia/silica beads.
The tubes were fixed in a TissueLyser homogenizer
(Qiagen, Venlo, Netherlands) and the cells were disrupted
by vortexing for 5 min at 30 Hz. The suspensions were
clarified by centrifugation (14,000 rpm for 10 min), and
the supernatant was used for DNA extraction with the
DNeasy Blood & Tissue kit (Qiagen) according to the man-
ufacturer’s protocol. The DNA concentration was quanti-
fied using a NanoDrop spectrophotometer (NanoDrop
Technologies, Wilmington, DE) at 260 nm.
Genotyping
Spa typing [19] and Multi Locus Sequence Typing (MLST)
[20] were performed as described previously. Spa types
were assigned by Ridom StaphType software version 1.4.6
(Ridom GmbH, Würzburg, Germany) and the Ridom
SpaServer (http://www.spaserver.ridom.de) [21] after
adhering to the SeqNet.org quality procedure [22]. A sin-
gle representative of each spa type was analyzed by
MLST. Sequences of each MLST locus were compared to
the data in the S.aureus MLST database (http://saureus.
mlst.net/), and resulting allelic profiles were assigned to
particular sequence types (STs) for each isolate. eBURST
software (v3, http://eburst.mlst.net) was used to classify
related Sequence Types (STs) into clonal complexes
(CCs) A singleton was defined as a sequence type that
did not group with any clonal complex. The diagnostic
DNA microarrays (StaphyType; Alere Technologies, Jena,
Germany) and StaphyType DNA microarray kit were
used for study of the presence of genes encoding spe-
cies markers, agr types and virulence factors as described
previously [23].
Results
Carriage of S.aureus
A total of 950 screening swabs were obtained from 733
inpatients in the medical, surgical and gynaecological
wards of Thika Hospital. Patients ranged in age between
1 and 90 years and 52% of screens were performed in
male patients (see Table 2). We found no association be-
tween carriage of S.aureus and either age-group or sex
(χ2 test; p > 0.1). As a result of the repeated rounds of
cross-sectional inpatient screening, an average of 1.4
screens were performed per patient over the study period
(range 1–8 screens; see Table 3).
A total of 85 inpatient screenings (85/950; 8.9%; 95%
CI 7.1-10.8) detected carriage of S.aureus. One patient
had two distinct S.aureus strains simultaneously (one
MRSA and one MSSA). Thus, a total of 86 S.aureus
isolates were collected. Species identification was con-
firmed by the presence of the S.aureus-specific genes
(spa, coA, nuc1) and mecA for MRSA. Among the S.aureus
isolates obtained, six (6/86; 7.0%; 95%CI 1.5-12.5%) were
Table 2 Patient characteristics in screening tests
Characteristic Screening
negative (%)
Any S.aureus
detected (%)
MRSA
detected (%)
Median age, years (range) 34 (1–90) 40 (2–80) 27 (2–57)
Age < 14 yrs 103 (12) 4 (5) 4 (67)
Male sex 450 (52) 48 (56) 4 (67)
Ward location
Surgical - Male 298 (52) 44 (34) 4 (67)
Surgical - Female 215 (25) 22 (26) 2 (33)
Medical - Male 127 (15) 7 (8) 0 (0)
Medical - Female 141 (16) 8 (9) 0 (0)
Gynaecology 84 (10) 4 (5) 0 (0)
Total 865 (100) 85 (100) 6 (100)
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MRSA. All of these were obtained from surgical pa-
tients, comprising three adult men and one male child
(male surgical ward) and one woman and one female
child (female surgical ward). All of these patients had
been hospitalised for a prolonged period, five with ex-
tensive burns and one with a fractured femur. The
median admission length prior to MRSA detection was
27 days (range 25–172 days). When comparing pa-
tients with single versus multiple rounds of screening
performed, there was evidence that having multiple
screens was associated with higher likelihood of S.aureus
being detected (χ2 test; p < 0.001 – see Table 3). Out of all
patients in the study, a total of 74 were found to have car-
riage of S.aureus in at least one screen (74/733; 10.1%;
95%CI 7.2-12.3).
Antibiotic resistance
All six MRSA isolates were co-resistant to gentamicin,
ciprofloxacin, tetracycline and co-trimoxazole and five
were also resistant to lincosamine and macrolide antibi-
otics. All MRSA isolates were susceptible to chloram-
phenicol, vancomycin and mupirocin. Amongst the MSSA
isolates obtained, resistance to penicillin, tetracycline and
SXT was common, but not to any other antibiotics – see
Table 4.
Diversity of isolates established by spa typing and
MLST analyses
The 86 S.aureus isolates were assigned to 28 spa types,
ranging in length between four (t10499) and 12 (t005)
repeats. Two new repeats, r558 and r559, and five new
spa types, t10496, t10497, t10498, t10499 and t10960,
were found and assigned over the course of this study.
Sixteen spa types were represented by 2 or more isolates
(73 isolates in total), while 13 spa types contained a sin-
gle isolate. All six MRSA isolates identified were of spa
type t037. Among the MSSA isolates, t223 (n = 15) was
the most frequent spa type, followed by t064 (n = 10) and
t131 (n = 10). Other spa types (n = 25) were represented
by four or less MSSA isolates. Isolates obtained from ini-
tial patient-screens were less likely to have spa types with
multiple (≥3) occurrences (39/57, 68%) than those isolates
obtained from subsequent rounds of screening (24/29,
83%), though this difference did not reach statistical signifi-
cance (χ2 test; p = 0.16).
Using MLST, twenty STs were identified. Five new
MLST allelic profiles and three new STs were found; the
latter were assigned as ST2429, ST2430, and ST2431.
All six MRSA isolates belonged to international clone
ST239. The correspondence between MLST and spa typ-
ing is shown in Table 5.
Using eBURSTv3, all MLST STs obtained in the study
were assigned to CCs. This method identified ST2430 as
a single locus variant of CC121; the remaining 18 STs
were unrelated. Subsequently, MLST data obtained in
this study were compared to the S.aureus MLST data-
base. Of the 68 isolates which were grouped into 14
CCs, the majority of these (64/68, 94%) had a founder
sequence type – see Table 5.
Table 3 Rounds of S.aureus screening amongst inpatients
Number of screens
performed
Number of
patients
Total number
of screens
S.aureus not
detected on screen
Screens with
MSSA detected
Screens with
MRSA detected
S.aureus ever detected
in patient (%)
1 609 609 566 39 4 43/609 (7.1%)
2 72 144 125 18 1 14/72 (19.4%)
3 27 81 74 7 0 5/27 (18.5%)
4 15 60 50 10 0 7/15 (46.7%)
5 7 35 33 2 0 2/7 (28.6%)
6 1 6 5 1 0 1/1 (100%)
7 1 7 4 3 0 1/1 (100%)
8 1 8 7 0 1 1/1 (100%)
Total 733 950 865 79 6 74/733 (10.1%)
Table 4 Sensitivity patterns of MRSA and MSSA carriage
isolates from Thika Hospital, Kenya
Antibiotic Proportion susceptible (%)
MSSA (n = 80) MRSA (n = 6)
Cefoxitin 100 0
Benzylpenicillin 26 0
Co-trimoxazole 60 0
Tetracycline 85 0
Gentamicin 99 0
Ciprofloxacin 100 0
Erythromicin/Clindamycin 99 17
Rifampicin 99 83
Chloramphenicol 100 100
Vancomycin 100 100
Mupirocin 100 100
Aiken et al. Antimicrobial Resistance and Infection Control 2014, 3:22 Page 4 of 7
http://www.aricjournal.com/content/3/1/22
Microarrays
The distribution of genes of the core variable genome
and the identification of the allelic variants of genes of
the core genome varied between MLST sequence type.
Amongst the 6 MRSA isolates, all carried the SCCmec
III element, but none carried the lukF/lukS (PVL) genes.
Amongst the 80 MSSA isolates, the frequency of car-
riage of the following genetic elements was as follows:
lukF-PV/lukS-PV (PVL; n = 15; 19%), toxic shock syn-
drome toxin 1 (tst1; n = 18; 23%), staphylococcal entero-
toxin a (sea, n = 17; 21%) and exfoliative toxin a (eta;
n = 6; 8%). Full details of the microarray results including
descriptions of profiles for all isolates are given as supple-
mentary material in Additional file 1.
Discussion
In this typical mid-sized Kenyan government hospital,
carriage of S.aureus amongst inpatients was found to be
relatively infrequent (8.9%; 95%CI 7.1-10.8) in individual
screens. Due to the repeating cross-sectional sampling
design, this result may underestimate the actual in-
patient prevalence due to a time-dependant bias [24] intro-
duced by only performing multiple rounds of screening
in patients with longer admissions. The actual prevalence
might be better estimated by the proportion of patients in
the study who were ever detected to have S.aureus carriage
(74/733; 10.1%; 95%CI 7.2-12.3) – though some of these
patients probably acquired carriage during admission.
MRSA constituted only 6.9% (95%CI 1.5-12.5%) of all S.
aureus isolates obtained. Both the overall carriage rate and
the proportion of MRSA were surprisingly low, given that
nasal carriage of S.aureus in European populations is typic-
ally around 25% [1,25] and the crowded conditions in
Thika Hospital should have led to frequent transmission
of MRSA. The small number of MRSA isolates obtained
leaves us with a wide confidence interval for the true
microbiological prevalence.
Almost all MRSA carriage was confined to patients
with burns who constituted approximately 10% of adult
inpatients admitted to the surgical wards and approxi-
mately 5% of inpatients overall. In sub-Saharan Africa,
prolonged hospital admission after burns injuries are
common [26], and as specialist burns units are rarely
available, these patients often make up a sizeable propor-
tion of the general inpatient population. Burns patients
are at increased risk of invasive bacterial disease [27] and
hence colonisation of these patients with a multi-drug re-
sistance organism is of particular concern. Chlorampheni-
col is a widely used 2nd line antibiotic in sub-Saharan
Africa and as all isolates in Thika Hospital were found to
be susceptible to this drug, this might be a suitable empir-
ical alternative to vancomycin for suspected MRSA infec-
tions in this setting.
These Thika MRSA isolates belong to the wide-
spread ST239 strain, formerly known as the Hungarian/
Brazilian epidemic strain which is typically associated with
hospital-acquisition. This has been documented to occur
in sub-Saharan Africa in Senegal, Niger [12], South Africa
[28] and was noted to be common amongst hospitalised
burns patients in Nigeria [10]. The pattern of multi-class
antibiotic resistance that we found in Thika Hospital is typ-
ical of this strain in African settings [12].
When designing this study, we expected S.aureus and
MRSA to occur considerably more frequently than we
actually found. We used a repeated cross-sectional ap-
proach for detecting carriage but this may have missed
some cases of nosocomial acquisition occurring late in
admission, which could have been detected by additional
screening on discharge.
The reason for the surprisingly low overall rate of
S.aureus carriage (8.9%) in our study is unclear. We
feel that is it unlikely that procedural errors with swab
collection could account for this – all swab collection
was supervised in person and regularly quality-controlled
by one investigator (AA) and an experienced researcher
(HG) made an on-site review of the collection and pro-
cessing methods in the first month of the study. The an-
terior nares and axillae are widely accepted to be reliable
Table 5 MLST and spa types from 86 S.aureus isolates
obtained at Thika Hospital, Kenya
MLST CC* ST within CC
(number of isolates)
spa types (number of isolates,
if >1 spa type)
CC22 ST22 (17) t223 (15), t005 (1), t10498 (1)
CC8 ST8 (14) t064 (10), t121 (3), t10497 (1)
CC121
ST2430 (4) t645
ST121 (3) t314
CC239 ST239 (6) t037†
CC97 ST97 (5) t359 (2), t1965 (2), t267 (1)
CC5 ST5 (3) t002
CC30 ST30 (3) t318
CC7 ST7 (3) t091
CC6 ST6 (2) t701
CC15 ST15 (2) t084 (1), t491 (1)
CC25 ST25 (2) t3772
CC72 ST72 (2) t148 (1), t4353 (1)
CC1 ST1 (1) t127
CC45 ST45 (1) t015
Singletons
ST1290 (10) t131
ST152 (4) t355
ST2431 (2) t10496
ST2019 (1) t10499
ST2429 (1) t10960
* = Clonal Complex nomenclature derived from MLST database.
† = all 6 isolates of t037 were MRSA, all other isolates were MSSA.
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sites for S.aureus detection [1] and we used an enrich-
ment culture intermediate step to assist with detection of
small numbers of organisms. However, we accept that
swabs from the skin surface have inherently limited sen-
sitivity to detect carriage organisms and we note that in
our study, patients who had multiple screenings per-
formed were more likely to ever have had S.aureus car-
riage detected. It is therefore possible that a single round
of screening is not sufficient to exclude carriage in this
setting. Alternatively, progressive acquisition of carriage
during hospital admission, as evidenced by our molecular
studies, could provide some explanation for this finding
of increasing carriage with repeated screening. Genetic
differences might also provide an explanation for a low
carriage rate – human genetic factors are thought to be
important determinants for persistent colonisation with
S.aureus [29].
There were some intriguing findings revealed by the
molecular analyses. In particular, we note that in com-
parison to isolate collections from other settings, there
were high proportions of isolates with genes for the
Panton-Valentine Leukocidin (PVL, 15/86, 19%) and toxic
shock syndrome toxin 1 (tst1, 18/86, 23%). From the per-
spective of staphylococcal classification systems, many of
the spa types (18%; 5/28) and MLST profiles (15%, 3/20)
identified in this population were novel. This is reflective
of the limited contribution of African sites to the relevant
typing databases. The lack of diversity amongst the MRSA
and MSSA isolates obtained in our institution over a four
month period suggests that these were probably being
transmitted by local (within-hospital) routes rather than
repeated introduction from external sources, though with-
out greater knowledge of the diversity of strains circulating
in Kenya or East Africa as a whole, we cannot be cer-
tain of this. Due to overcrowding and lack of isolation
facilities, eliminating nosocomial transmission of organ-
isms such as MRSA in institutions like Thika Hospital will
be challenging.
Antibiotic resistance is a growing concern in develop-
ing countries [30] and local studies are needed to under-
stand the transmission of drug-resistant organisms and
guide strategies for containment. MRSA is an important
nosocomial pathogen in developed countries but is little-
known in sub-Saharan Africa. This is the largest study
examining inpatient carriage of S.aureus in sub-Saharan
Africa and it was conducted in a typical mid-sized Kenyan
Government Hospital. We found inpatient carriage of
MRSA to be relatively infrequent and was mainly confined
to patients with burns. The lack of genetic diversity
amongst the isolates obtained suggests “within-hospital”
transmission. The multiple drug resistance of MRSA
found in Thika hospital coupled with the vulnerability of
burns patients to invasive bacterial infection is a cause
for concern. Thika Hospital faces many infection control
challenges that are typical of those encountered in African
healthcare facilities. Much work is needed in Kenya and
throughout the region to formulate appropriate national
and local policies to tackle issues such as MRSA and, more
importantly, to put these into effective practice.
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